New Technology– category –
-
BeOne Medicines’ BEQALZI™ (Sonrotoclax) Gains US FDA Approval for Relapsed/Refractory Mantle Cell Lymphoma as First BCL2 Inhibitor
Stock Titan USA Overview BeOne Medicines announced that BEQALZI™ (sonrotoclax) has received U.S. FDA approval for the treatment of relapsed/refractory Mantle Cell Lymphoma (MCL), marking it as the first BCL2 inhibitor for this indication... -
GSK’s Bepirovirsen for Chronic Hepatitis B Receives FDA Priority Review and Breakthrough Therapy Designation
GSK USA Overview GSK announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, a candidate for chronic Hepatitis B, has been granted both Priority Review and Breakthrough Therapy Designation (BTD) by the U.S. FDA.... -
Incyte Partners with Edison Scientific to Integrate “Kosmos” AI Platform for Enhanced Drug Discovery and Development
Investing.com Canada USA Overview Incyte has announced a partnership with Edison Scientific to integrate Edison's AI platform, "Kosmos," into its drug discovery and development processes. This collaboration focuses on target discovery, v... -
GLP-1 Gene Therapy Enters First Human Clinical Trials; Endometriosis Poised for First Disease-Modifying Treatment
DDN Magazine USA Overview This week's DDN Weekly Rundown reports that GLP-1 gene therapy has advanced into its first human clinical trials, alongside the potential emergence of the first disease-modifying therapy for endometriosis. The e... -
FDA Grants Breakthrough Therapy Designation to Chronic Low Back Pain Treatment, Signaling Potential Shift for Cannabinoid-Derived Therapies
YouTube (CB1 Capital) USA Overview The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for a treatment for chronic low back pain. This announcement potentially signals an emerging wave of designations for cannabinoid-derived ... -
Isomorphic Labs Secures $2.1 Billion to Scale AI Drug Discovery Engine, Eyes First AI-Designed Drug in Human Trials by Year-End
AI Healthcare News USA Overview Isomorphic Labs, Alphabet's AI drug discovery arm, has raised a staggering $2.1 billion to expand its "IsoDDE" AI engine. Leveraging AI in conjunction with AlphaFold 3, the company develops a platform to p... -
Incyte and Genesis Molecular AI Expand Partnership to Accelerate AI-Driven Drug Discovery with Over $1 Billion in Milestones
Forbes USA Overview Incyte has significantly expanded its strategic collaboration with Genesis Molecular AI, integrating AI platforms with proprietary experimental data to accelerate novel molecule discovery. This enhanced partnership, p... -
Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company USA Overview Eli Lilly's triple-agonist retatrutide, targeting GIP, GLP-1, and glucagon receptors, demonstrated powerful efficacy in its pivotal Phase 3 TRIUMPH-1 trial for obesity. Patients receiving the highest do... -
Cross-Linked Polyethylene Glycol Networks as Flexible Solid Electrolytes for Sodium Batteries Demonstrate High Ionic Conductivity and Long-Term Stability
MDPI Switzerland Overview This MDPI paper reports on the development of flexible, cross-linked polyethylene glycol (PEG) network-based solid electrolytes for all-solid-state sodium batteries. The NPC1000-NaClO4 electrolyte achieved an io... -
Anode-Free Cells and Solid-State Batteries: A Comparative Performance Review Highlights Key Advances
PatSnap Eureka Singapore Overview A PatSnap Eureka report provides a comparative performance review of anode-free cells and solid-state batteries, two leading next-generation battery technologies. Solid-state batteries, leveraging divers...
